Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting

News provided by

Jun 17, 2020, 09:00 ET

SHANGHAI, June 17, 2020 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company focused on the discovery and development of next-generation of immunomodulatory small molecules for the treatments of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders, today announced that two posters highlighting preclinical data of the company's lead drug candidates, KPG-121 and KPG-818, will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II to be held from June 22-24, 2020.

Details of the e-poster presentations on June 22-24 are as follows:

Abstract Title: KPG-121, A Novel Cereblon Modulator, Potently Inhibits Growth of Metastatic Castration Resistant Prostate Cancer in Combination with Androgen Receptor Inhibitors Both In Vitro and In Vivo
Abstract Number: 5300
Poster Number: 5327
Poster Session: Novel Antitumor Agents 2

KPG-121 is a novel modulator of the Cerebron (CRBN) E3 ubiquitin ligase complex CRL4^CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1α) and transcription factors Aiolos and Ikaros. KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. KPG-121 significantly improves anti-tumor efficacies when combined with androgen-receptor antagonists including Enzalutamide, Abiraterone Acetate, Apalutamide, or Darolutamide in xenograft models when compared to the androgen-receptor antagonist therapy alone. KPG-121 is currently being evaluated in a Phase I study in the US for the treatment of patients with metastatic and non-metastatic castration-resistant prostate cancer in combination with Enzalutamide, Abiraterone Acetate, or Apalutamide (NCT03569280 at www.clinicaltrials.gov).

Abstract Title: KPG-818, A Novel Cereblon Modulator, Inhibits Hematological Malignancies in Preclinical Models
Abstract Number: 5671
Poster Number: 6367
Poster Session: Novel Antitumor Agents 3

KPG-818 represents a novel generation of small molecule modulators of the CRBN E3 ubiquitin ligase complex CRL4^CRBNand potently induces the ubiquitination and degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two members of the Ikaros family of zinc-finger transcription factors critical in B-cell development. In preclinical studies, KPG-818 demonstrates outstanding in vitro anti-inflammatory properties and broad spectrum of anti-proliferative activities as well as remarkable in vivo efficacy in animal models of multiple blood cancers. KPG-818 is currently being developed in a Phase I study for the treatment of patients with hematological malignancies in the US (NCT04283097 at www.clinicaltrials.gov).

Abstracts and full session details can be found at www.aacr.org.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory disorders through novel-generation solutions including targeted protein ubiquitination and degradation. Led by a highly experienced and dedicated management team, Kangpu has built a rich and solid pipeline of potential first-in-class and best-in-class drug candidates. The company has also developed X-Synergy^®, a proprietary drug combination technology for the treatment of metastatic and non-metastatic castration-resistant prostate cancer.

For more information, please visit www.KangpuGroup.com.

Media Contact

Kangpu Biopharmaceuticals, Ltd.
Stella Yan
Director, Corporate Communications
[email protected]
+86 21 58433625

SOURCE Kangpu Biopharmaceuticals